The WHO 2022/2023 classification refines HL subtyping by recognizing LRcHL as a distinct cHL subtype that, while it may mimic the nodular, lymphocyte-rich architecture of NLPHL, is defined by cHL markers such as CD30 and CD15, highlighting blurred diagnostic boundaries. This evidence concerns the gene TNFRSF8 and classic Hodgkin lymphoma.